Home » Stocks » TMDX

TransMedics Group, Inc. (TMDX)

Stock Price: $22.75 USD -2.21 (-8.85%)
Updated May 6, 2021 4:00 PM EDT - Market closed
After-hours: $22.22 -0.53 (-2.33%) May 6, 5:36 PM
Market Cap 689.47M
Revenue (ttm) 25.64M
Net Income (ttm) -28.75M
Shares Out 27.62M
EPS (ttm) -1.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $22.75
Previous Close $24.96
Change ($) -2.21
Change (%) -8.85%
Day's Open 23.87
Day's Range 22.42 - 24.21
Day's Volume 718,202
52-Week Range 11.51 - 49.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

TransMedics (TMDX) delivered earnings and revenue surprises of -3.57% and 1.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 day ago - Zacks Investment Research

Shares of TransMedics Group (NASDAQ:TMDX) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 30.95% over the past year to ($0.29), whic...

2 days ago - Benzinga

ANDOVER, Mass., May 4, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage...

2 days ago - PRNewsWire

TransMedics is looking to disrupt an entire industry and help thousands of transplant patients in the U.S. in the process.

2 weeks ago - The Motley Fool

ANDOVER, Mass., April 20, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...

2 weeks ago - PRNewsWire

The FDA Advisory Committee has voted in favor of TransMedics Group Inc (NASDAQ: TMDX) after reviewing clinical evidence from the OCS Heart EXPAND trial, the associated Continued Access Protocol (CAP) re...

4 weeks ago - Benzinga

ANDOVER, Mass., April 6, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

4 weeks ago - PRNewsWire

Jonah Lupton of Lupton Capital was focused on TransMedics Group Inc (NASDAQ: TMDX) Tuesday. The Nasdaq halted trading in TransMedics stock while the FDA reviews the company's OCS Heart System.

1 month ago - Benzinga

ANDOVER, Mass., April 6, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

1 month ago - PRNewsWire

ANDOVER, Mass., March 24, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...

1 month ago - PRNewsWire

And it probably won't take them long to do it.

Other stocks mentioned: AYRWF, GHVIU
1 month ago - The Motley Fool

TransMedics (TMDX) delivered earnings and revenue surprises of 8.00% and 24.62%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of TransMedics Group (NASDAQ:TMDX) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 46.51% over the past year to ($0.23), w...

2 months ago - Benzinga

ANDOVER, Mass., March 2, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

2 months ago - PRNewsWire

ANDOVER, Mass., March 1, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

2 months ago - PRNewsWire

ANDOVER, Mass., Feb. 16, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

2 months ago - PRNewsWire

ANDOVER, Mass., Feb. 16, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

2 months ago - PRNewsWire

Abrams Capital Management leader David Abrams (Trades, Portfolio) revealed earlier this week he reduced his stake in TransMedics Group Inc. (NASDAQ:TMDX) by 25.01%.

2 months ago - GuruFocus

Corcept Therapeutics (NASDAQ: CORT) shares were trading lower Tuesday after the company reported preliminary fourth-quarter sales results and issued fiscal year 2021 sales guidance. Corcept Therapeutics...

Other stocks mentioned: ACST, CORT, KLDO
2 months ago - Benzinga

TransMedics saw steady growth in 2019 after the public offering. Its transformative approach to organ transplantation has real benefits and seems to have traction as well, with Covid-19 only showing ado...

3 months ago - Seeking Alpha

ANDOVER, Mass., Dec. 24, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

4 months ago - PRNewsWire

ANDOVER, Mass., Dec. 23, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

4 months ago - PRNewsWire

LONDON--(BUSINESS WIRE)--Deep Pharma Intelligence names Nanox Imaging (NASDAQ:NNOX), TransMedics, Inc. (NASDAQ: TMDX), Outset Medical, Inc. (NASDAQ:OM), Eargo, Inc. (NASDAQ:EAR), and Silk Road Medical, ...

Other stocks mentioned: EAR, NNOX, OM, SILK
4 months ago - Business Wire

Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.

Other stocks mentioned: MYO, XGN
4 months ago - Zacks Investment Research

TransMedics Group's (TMDX) CEO Waleed Hassanein on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

TransMedics (TMDX) delivered earnings and revenue surprises of 42.42% and 19.58%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

ANDOVER, Mass., Nov. 4, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stag...

6 months ago - PRNewsWire

ANDOVER, Mass., Oct. 29, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

6 months ago - PRNewsWire

TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

ANDOVER, Mass., Oct. 21, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

6 months ago - PRNewsWire

ANDOVER, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...

7 months ago - GlobeNewsWire

ANDOVER, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...

8 months ago - GlobeNewsWire

TransMedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

ANDOVER, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with e...

9 months ago - GlobeNewsWire

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Other stocks mentioned: HCAT, RMD
9 months ago - Zacks Investment Research

TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

ANDOVER, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with e...

9 months ago - GlobeNewsWire

ANDOVER, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with e...

9 months ago - GlobeNewsWire

TransMedics: A Medical Device Company Creating A Healthy Ecosystem

11 months ago - Seeking Alpha

Shares slumped after the company announced it's raising capital.

11 months ago - The Motley Fool

ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with en...

11 months ago - GlobeNewsWire

ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with en...

11 months ago - GlobeNewsWire

Primary Effectiveness and Safety Endpoints Were Met. The OCS Liver Achieved Statistical Superiority of The Primary Effectiveness Endpoint by Demonstrating Significant Reduction of Early Allograft Dysfun...

11 months ago - GlobeNewsWire

TransMedics Group's (TMDX) CEO Waleed Hassanein on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

TransMedics Expects Strong 2020 Growth Trajectory

1 year ago - Seeking Alpha

ANDOVER, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...

1 year ago - GlobeNewsWire

TransMedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Disrupting Organ Transplants: TransMedics And In-Kind Competitors

1 year ago - Seeking Alpha

TransMedics (TMDX) successfully completes heart transplants from DCD donors, using its OCS technology.

1 year ago - Zacks Investment Research

The current transportation process is riddled with inefficiencies and waste. TransMedics is on a mission to fix the problem and deliver huge returns for investors.

1 year ago - The Motley Fool

About TMDX

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system tha... [Read more...]

Industry
Medical Devices
IPO Date
May 2, 2019
Stock Exchange
NASDAQ
Ticker Symbol
TMDX
Full Company Profile

Financial Performance

In 2020, TMDX's revenue was $25.64 million, an increase of 8.62% compared to the previous year's $23.60 million. Losses were -$28.75 million, -14.31% less than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price forecast is 53.00, which is an increase of 132.97% from the latest price.

Price Target
$53.00
(132.97% upside)
Analyst Consensus: Buy